Home > Insider Trading > Filing (0000899243-23-013992)

Filing Details

Accession Number:: 0000899243-23-013992
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-05-26 20:00:11
Reporting Period:: 2023-05-24

Accepted Time:: 2023-05-26 20:00:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1770121	Sana Biotechnology Inc.	SANA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1627639	Flagship Ventures Fund V, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1724575	Flagship Ventures Fund V General Partner Llc	55 Cambridge Parkway Suite 800E Cambridge MA 02142	No	No	Yes	No
1724939	Flagship V Venturelabs Rx Fund, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-05-24	308,290	$6.57	11,276,909	No	4	S	Indirect	By Flagship Ventures Fund V, L.P.
Common Stock	Disposition	2023-05-24	39,580	$6.57	1,447,791	No	4	S	Indirect	By Flagship V VentureLabs Rx Fund, L.P.
Common Stock	Disposition	2023-05-25	102,245	$6.35	11,174,664	No	4	S	Indirect	By Flagship Ventures Fund V, L.P.
Common Stock	Disposition	2023-05-25	13,127	$6.35	1,434,664	No	4	S	Indirect	By Flagship V VentureLabs Rx Fund, L.P.
Common Stock	Disposition	2023-05-26	72,670	$6.23	11,101,994	No	4	S	Indirect	By Flagship Ventures Fund V, L.P.
Common Stock	Disposition	2023-05-26	9,330	$6.23	1,425,334	No	4	S	Indirect	By Flagship V VentureLabs Rx Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Flagship Ventures Fund V, L.P.
No	4	S	Indirect	By Flagship V VentureLabs Rx Fund, L.P.
No	4	S	Indirect	By Flagship Ventures Fund V, L.P.
No	4	S	Indirect	By Flagship V VentureLabs Rx Fund, L.P.
No	4	S	Indirect	By Flagship Ventures Fund V, L.P.
No	4	S	Indirect	By Flagship V VentureLabs Rx Fund, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,441,326	Indirect	By Flagship VentureLabs V, LLC
Common Stock	9,725,122	Indirect	By Flagship Pioneering Fund VI, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.56, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents shares held directly by Flagship VentureLabs V LLC. ("VentureLabs V"). VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.